Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer

European Journal of Oncology Nursing

Volumn 14, Issue 4, 2010, Pages 337-349

  Ouwerkerk, Jan ^a   Boers Doets, Christine ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Waterland Hospital   (Netherlands)

Author keywords

Anti EGFR agents; Cetuximab; Colorectal cancer; Dermatologic; Diarrhoea; Hypomagnesaemia; Infusion reactions; Ocular; Panitumumab; Toxicities

Indexed keywords

EID: 77955664258     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2010.03.004     Document Type: Article

References (72)

1. Agero A., Dusza S.W., Benvenuto-Andrade C., Busam K.J., Myskowski P., Halpern A.C. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology 2006, 55:657-670.
2. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:1626-1634.
3. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nursing 2007, 30:S10-S16.
4. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Research 2007, 67:2643-2648.
5. Berlin J., Van Cutsem E., Peeters M., Hecht J.R., Ruiz R., Wolf M., Amado R.G., Meropol N.J. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. Journal of Clinical Oncology 2007, 25:18s. (abstr 4134).
6. Boers-Doets, C., Ouwerkerk, J., August 17-21, 2008. EGFR-Inhibitors induced skin reactions. Presented at the International Society of Nurses in Cancer Care Conference, Singapore, China.
7. Bokemeyer C., Bondarenko I., Makhson A., Hartmann J.T., Aparicio J., de Braud F., Donea S., Ludwig H., Schuch G., Stroh C., Loos A.H., Zubel A., Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2009, 27:663-671.
8. Boone S.L., Rademaker A., Liu D., Pfeiffer C., Mauro D.J., Lacouture M.E. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007, 72:152-159.
9. Bouche O., Brixi-Benmansour H., Bertin A., Perceau G., Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Annals of Oncology 2005, 16:1711-1712.
10. Burtness B., Anadkat M., Basti S., Hughes M., Lacouture M.E., McClure J.S., Myskowski P.L., Paul J., Perlis C.S., Saltz L., Spencer S. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal of the National Comprehensive Cancer Network 2009, 7(Suppl. 1):S5-S21. quiz S22-S24.
11. Carson E.J., Novak A.M., Stella P.J. Hypomagnesemia in patients with stage IV colorectal cancer treated with cetuximab as a single agent. Journal of Clinical Oncology 2005, 23(Suppl. 16s). (abstr 3655).
12. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology 2005, 23:1803-1810.
13. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. New England Journal of Medicine 2008, 358:1160-1174.
14. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004, 351:337-345.
15. Dick S.E., Crawford G.H. Managing cutaneous side effects of epidermal growth factor receptor (HER2/EGFR) inhibitors. Community Oncology 2005, 2:492-496.
16. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., Bastit L., Killian A., Sesboüé R., Tuech J.J., Queuniet A.M., Paillot B., Sabourin J.C., Michot F., Michel P., Frebourg T. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. British Journal of Cancer 2007, 96:1166-1169.
17. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., Jandik P., Iveson T., Carmichael J., Alakl M., Gruia G., Awad L., Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as the first-line treatment for metastatic colorectal cancer. A multicentre randomised trial. Lancet 2000, 355:1041-1047.
18. Dranko S., Kinney C., Ramanathan R.K. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clinical Colorectal Cancer 2006, 6:224-225.
19. Dueland S., Sauer T., Lund-Johansen F., Ostenstad B., Tveit K.M. Epidermal growth factor receptor inhibitor induces trichomegaly. Acta Oncology 2003, 42:345-346.
20. Erbitux (Cetuximab) Prescribing Information 2008, Available from:, Bristol-Meyers Squbb, Branchburg, NJ, (accessed 9 July 2009). http://packageinserts.bms.com/pi/pi_erbitux.pdf.
21. Erbitux (Cetuximab) Summary of Product Characteristics 2009, Merck KGaA, Darmstadt, Germany, Available from:(accessed 11 November 2008). http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdf.
22. Fakih M.G., Wilding G., Lombardo J. Cetuximab-induced hypomagnesaemia in patients with colorectal cancer. Clinical Colorectal Cancer 2006, 6:152-156.
23. Foerster C.G., Cursiefen C., Kruse F.E. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008, 27:612-614.
24. Galimont-Collen A.F.S., Vos L.E., Lavrijsen A.P.M., Ouwerkerk J., Gelderblom H. Classification and management of skin, hair, nail, and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer 2007, 43:845-851.
25. Greil R., Letocha H., Gamelin E., Thaler J., Hofheinz R., Mineur L., Thaler J., Hofheinz R., Mineur L., Fernebro E., Karthaus M., Wright L., Köhne C. Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 2009, 27(Suppl. 15s). (abstr 4085).
26. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park) 2006, 20:21-28.
27. Grothey A., Sargent D., Goldberg R.M., Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. Journal of Clinical Oncology 2004, 22:1209-1214.
28. Hecht, J., Mitchell, E.P., Baranda, J., Richards, D., Reiner, M., Stout, S., Amado, R.G., 2008. Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): final efficacy and KRAS analyses. In: Presented at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 25-27, 2008; Orlando, FL (abstract 343).
29. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350:2335-2342.
30. Jatoi A., Rowland K., Sloan J.A., Gross H.M., Fishkin P.A., Kahanic S.P., Novotny P.J., Schaefer P.L., Johnson D.B., Tschetter L.K., Loprinzi C.L. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008, 113:847-853.
31. Jean G.W., Shah S.R. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008, 28:742-754.
32. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H.J., Berry S.R., Krahn M., Price T., Simes R.J., Tebbutt N.C., van Hazel G., Wierzbicki R., Langer C., Moore M.J. Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007, 357:2040-2048.
33. Kang S.P., Saif M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies use to treat colorectal cancer-identification, prevention, and treatment. The Journal of Supportive Oncology 2007, 5:451-457.
34. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 2008, 359:1757-1765.
35. Lacouture, M.E. Mitchell, E.P., Shearer, H., Iannotti, N., Piperdi, B., Pillai, M.V., Xu, F., Yassine, M., 2009. Impact of pre-emptive skin toxicity (ST) treatment (tx) on panitumumab (pmab)-related skin toxicities and quality of life (QOL) in patients (pts) with metastatic colorectal cancer (mCRC): results from STEPP. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, January 15-17, 2009; San Francisco, CA (abstract 291).
36. Lacouture M.E. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nursing 2007, 30:S17-S25.
37. Lacouture M.E., Basti S., Patel J., Benson A. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. The Journal of Supportive Oncology 2006, 4:236-238.
38. Lee J.J., Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clinical Colorectal Cancer 2007, 6:S42-S46.
39. Lemmens, L., 2008. Personalised cancer therapy: what is KRAS and what does it mean for patients with metastatic colorectal cancer? EONS Newsletter. Fall, 28-31.
40. Lenz H.J., Van Cutsem E., Khambata-Ford S., Mayer R.J., Gold P., Stella P., Mirtsching B., Cohn A.L., Pippas A.W., Azarnia N., Tsuchihashi Z., Mauro D.J., Rowinsky E.K. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Journal of Clinical Oncology 2006, 24:4914-4921.
41. Lievre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of Clinical Oncology 2008, 26:374-379.
42. Lynch T.J., Kim E.S., Eaby B., Garey J., West D.P., Lacouture M.E. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007, 12:610-621.
43. Melosky B., Burkes R., Rayson D., Alcindor T., Shear N., Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Current Oncology 2009, 16:16-26.
44. Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.0 2009, National Cancer Institute, Available from:(accessed November 15, 2009). http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev4.pdf.
45. Oishi K. Clinical approaches to minimize rash associated with EGFR inhibitors. Oncology Nursing Forum 2008, 35:103-111.
46. Peeters M., Wilson G., Ducreux M., Cervantes A., André T., Hotko Y., Lordick F., Collins S., Shing M., Price T.J. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results. Journal of Clinical Oncology 2008, 26(Suppl. 15s). (abstr 4064).
47. Perez-Soler R., Delord J.P., Halpern A., Kelly K., Krueger J., Sureda B.M., von Pawel J., Temel J., Siena S., Soulières D., Saltz L., Leyden J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10:345-356.
48. Peréz-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. Journal of Clinical Oncology 2005, 23:5235-5246.
49. Pohl A., Zhang W., Ning Y., Manegold P.C., Lurje G., Lenz H.-J. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. Oncology 2008, 22:456-462.
50. Saltz L.B. Understanding and managing chemotherapy-induced diarrhea. The Journal of Supportive Oncology 2003, 1:35-46.
51. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2000, 343:905-914.
52. Saltz L.B., Lenz H.J., Kindler H.L., Hochster H.S., Wadler S., Hoff P.M., Kemeny N.E., Hollywood E.M., Gonen M., Quinones M., Morse M., Chen H.X. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in the irinotecan-refractory colorectal cancer. Journal of Clinical Oncology 2007, 25:4557-4561.
53. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol 2004, 22:1201-1208.
54. Schrag D., Chung K.Y., Flombaum C., Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. Journal of National Cancer Institute 2005, 97:1221-1224.
55. Scope A., Agero A.L., Dusza S.W., Myskowski P.L., Lieb J.A., Saltz L., Kemeny N.E., Halpern A.C. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Journal of Clinical Oncology 2007, 25:5390-5396.
56. Segaert S., Chiritescu G., Lemmens L., Dumon K., Van Cutsem E., Tejpar S. Skin toxicities of targeted therapies. European Journal of Cancer 2009, 45(Suppl. 1):295-308.
57. Siena S., Sartore-Bianchi A., Di Nicolantonio F., Balfour J., Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Journal of National Cancer Institute 2009, 101:1308-1324.
58. Siena S., Tabernero J., Burkes R.L., Cassidy J., Cunningham D., Barugel M.E., Humblet Y., McPhie C., Shing M., Douillard J. Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): pooled safety data. Journal of Clinical Oncology 2008, 26(Suppl. 15s). (abstr 4034).
59. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Seminars in Oncology Nursing 2006, 22:28-34.
60. Sobrero A.F., Maurel J., Fehrenbacher L., Scheithauer W., Abubakr Y.A., Lutz M.P., Vega-Villegas M.E., Eng C., Steinhauer E.U., Prausova J., Lenz H.J., Borg C., Middleton G., Kröning H., Luppi G., Kisker O., Zubel A., Langer C., Kopit J., Burris H.A. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26:2311-2319.
61. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C., de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer. A randomized GERCOR study. Journal of Clinical Oncology 2004, 22:229-237.
62. Vaccaro M., Pollicino A., Barbuzza O., Guarneri B. Trichomegaly of the eyelashes following treatment with cetuximab. Clinical and Experimental Dermatology 2009, 34:402-403.
63. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., Pintér T., Lim R., Bodoky G., Roh J.K., Folprecht G., Ruff P., Stroh C., Tejpar S., Schlichting M., Nippgen J., Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New England Journal of Medicine 2009, 360:1408-1417.
64. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J.L., Van Laethem J.L., Maurel J., Richardson G., Wolf M., Amado R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007, 25:1658-1664.
65. Vano-Galvan S., Moreno-Martin P., Jaén P. Progressive trichomegaly. The Netherlands Journal of Medicine 2009, 67:35-36.
66. Vectibix (Panitumumab) Prescribing Information 2008, Available from:, Amgen, Inc., Thousand Oaks, CA, (accessed 9 July 2009). http://www.vectibix.com/pdfs/misc/vectibix_pi.pdf.
67. Vectibix (Panitumumab) Summary of Product Characteristics 2009, Available from:, Amgen Europe BV, Breda, The Netherlands, (accessed 11 November 2008). http://www.emea.europa.eu/humandocs/PDFs/EPAR/vectibix/H-741-PI-en.pdf.
68. Viale P.H., Sommers R. Nursing care of patients receiving chemotherapy for metastatic colorectal cancer: implications of the treatment continuum concept. Seminars in Oncology Nursing 2007, 23:22-35.
69. Wu M., Rivkin A., Pham T. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clinical Therapeutics 2008, 30:14-30.
70. Zhang G., Basti S., Jampol L.M. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of the literature. Cornea 2007, 26:858-860.
71. Zhang W., Gordon M., Lenz H.J. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Annals of Medicine 2006, 38:545-551.
72. Zuckerman D.S., Clark J.W. Systemic therapy for metastatic colorectal cancer: current questions. Cancer 2008, 112:1879-1891.